Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

SI-BONE Earnings Call: Key Takeaways

SI-BONE delivered a strong Q2 2026 with 15% revenue growth and significant adjusted EBITDA improvement, driven by broad-based procedure volume and favorable CMS reimbursement updates for its Granite and SI joint portfolios.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthU.S. revenue $53.2M (up 14.7%); International $2.8M (up 25.9%).
Mgmt ConfidenceHigh confidence in 2027 momentum from new products and reimbursement tailwinds.
Demand VisibilityStrong sequential U.S. procedure volume growth of 9% in Q2.
Margin TrendsGross margin stable at 79.5%; adjusted EBITDA improved 178% to $2.8M.
Op. LeverageRevenue grew twice as fast as operating expenses (7.7% expense growth).
Pricing PowerStable ASPs; guidance assumes low single-digit degradation from product mix shifts.
Vol vs PriceGrowth led by 15% U.S. procedure volume increase; ASPs remained stable.
Segment GrowthDouble-digit growth in SI joint fusion, pelvic fixation, and pelvic trauma.
New ClientsActive physicians grew 19% to 1,715; Smith & Nephew partnership progressing.
Capex & Debt$145.9M cash; investing in surgical capacity and new headquarters build-out.
Regulatory510K submitted for third breakthrough device; CMS finalized favorable DRG increases.
CommentaryShifting from a sacro-pelvic leader to a broader spinal-pelvic compromised bone company.
New LaunchesThird breakthrough device launch planned for Q4 2026, potentially October.

Growth

Worldwide revenue grew 15.2% to $56M; U.S. procedure volume increased 15% with double-digit growth across all modalities.

Outlook

Raised 2026 revenue floor to $231M-$233M; targeting 100 territory managers and phased Q4 breakthrough device launch.

Risks

Management pivoted to 'thoughtful guidance philosophy' when questioned on implied H2 U.S. revenue deceleration despite new catalysts.

Source

The company's earnings call, NASDAQ: SIBN, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

SI-BONE, Inc.: key numbers

Share price
$23.41Close, Nov 16
Market cap
$1.06B
Shares outstanding
45.11MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from SI-BONE, Inc.

All →
5:03 PM ET Form 4
Insider Selling

SI-BONE CEO Laura Francis Sells $1.9M of Stock

Laura Francis, CEO, sold 75,000 shares of SI-BONE, Inc. at $25.30 a share, worth $1.9M in total on Nov 4, 2026. Shares held after the trade: 304,256 (-19.8%).

Value
$1.9M
Shares
75,000
Price
$25.30
Role
CEO
Holding change
-19.8%
Trade date
Nov 4, 2026
5:02 PM ET Form 4
Insider Selling

SI-BONE SVP, Ops & Adm/Chief Legal Ofr Michael A. Pisetsky Sells $899K of Stock

Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Ofr, sold 36,241 shares of SI-BONE, Inc. at $24.80 a share, worth $899K in total on Nov 4, 2026. Shares held after the trade: 40,167 (-47.4%).

Value
$899K
Shares
36,241
Price
$24.80
Role
SVP, Ops & Adm/Chief Legal Ofr
Holding change
-47.4%
Trade date
Nov 4, 2026
5:00 PM ET Form 4
Insider Selling

SI-BONE Chief Op & Financial Officer Anshul Maheshwari Sells $81.2K of Stock

Anshul Maheshwari, Chief Op & Financial Officer, sold 3,247 shares of SI-BONE, Inc. at $25.00 a share, worth $81.2K in total on Nov 4, 2026. Shares held after the trade: 211,250 (-1.5%).

Value
$81.2K
Shares
3,247
Price
$25.00
Role
Chief Op & Financial Officer
Holding change
-1.5%
Trade date
Nov 4, 2026
4:55 PM ET Form 4
Insider Selling

SI-BONE Director Jeffrey W. Dunn Sells $418K of Stock

Jeffrey W. Dunn, Director, sold 20,000 shares of SI-BONE, Inc. at $20.89 a share, worth $418K in total on Nov 2, 2026. Shares held after the trade: 16,057 (-55.5%).

Value
$418K
Shares
20,000
Price
$20.89
Role
Director
Holding change
-55.5%
Trade date
Nov 2, 2026
4:08 PM ET 10-Q
Financial Results ▶ Call

SI-BONE Q3 2026 Results: Net Loss of $3.62M, Loss Narrows

SI-BONE, Inc. reported revenue of $55.7 million for the third quarter of 2026, representing a 14.5% increase over the same period in 2025. The company reduced its quarterly net loss to $3.6 million compared to $4.6 million in the prior year, driven by improved gross margins and controlled operating expense growth.

Key figure
Net loss $3.62M
5:19 PM ET Form 4
Insider Selling

SI-BONE SVP, Ops & Adm/Chief Legal Ofr Michael A. Pisetsky Sells $656K of Stock

Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Ofr, sold 29,665 shares of SI-BONE, Inc. at $22.11 a share, worth $656K in total on Oct 29, 2026. Shares held after the trade: 164,444 (-15.3%).

Value
$656K
Shares
29,665
Price
$22.11
Role
SVP, Ops & Adm/Chief Legal Ofr
Holding change
-15.3%
Trade date
Oct 29, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.